Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2016
|
| gptkbp:approvedBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:ATCCode |
J06BC04
|
| gptkbp:developedBy |
gptkb:Human_Genome_Sciences
|
| gptkbp:genericName |
gptkb:obiltoxaximab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
GlaxoSmithKline
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
gptkb:Bacillus_anthracis_protective_antigen
|
| gptkbp:usedFor |
treatment of inhalational anthrax
prevention of inhalational anthrax |
| gptkbp:bfsParent |
gptkb:Raxibacumab
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
ABthrax
|